Vasoplegia clinical trials at UCSF

1 research study open to eligible people

Vasoplegia is when blood vessels fail to constrict properly, leading to low blood pressure. UCSF is examining Angiotensin II's effectiveness and safety as a backup treatment during liver transplant procedures. Understanding its effects may improve surgical care.

Showing trials for

  • Angiotensin II in Liver Transplantation

    open to eligible people ages 18 years and up

    The purpose of this study is to determine the efficacy and safety of Angiotensin II as a second-line vasopressor (drug that raises the blood pressure) during liver transplantation.

    San Francisco, California

Our lead scientists for Vasoplegia research studies include .

Last updated: